SCYX Stock Recent News

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022.

Scynexis launched a product for VVC where there is no significant commercial demand. An additional indication in preventing VVC is not likely to significantly increase sales.

JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of oral ibrexafungerp for the treatment of patients intolerant of, or with fungal disease refractory to, standard antifungal therapy will be presented during IDWeek 2022 being held in Washington, D.C October 19-23, 2022.

JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Annual Global Investment Conference and the Ladenburg Thalmann Annual Healthcare Conference.

SCYNEXIS, Inc. (NASDAQ:SCYX ) Q2 2022 Results Conference Call August 15, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications and IR Dr. Marco Taglietti - President and CEO Christine Coyne - Chief Commercial Officer Dr. David Angulo - Chief Medical Officer Larry Hoffman - Interim CFO Conference Call Participants Carvey Leung - Cantor Fitzgerald Farhana Sakloth - Ladenburg Thalmann Oren Livnat - H.C. Wainwright Kumar Raja - Brookline Capital Markets Steve Brozak - WBB Securities Operator Ladies and gentlemen, good morning, and welcome to SCYNEXIS, Inc. Second Quarter 2022 Earnings Conference Call.

Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Monday, August 15, 2022 to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022.

JERSEY CITY, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from the CANDLE 304s nested sub-study of ibrexafungerp for prevention of recurrent vulvovaginal candidiasis (RVVC) will be presented during the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update being held in Dublin, Ireland, July 15-20, 2022.

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.